She stood up from the couch and her heart rate jumped to 140. By the time she reached the kitchen, she was gripping the counter, vision narrowing, waiting for the room to stop tilting. She sat down on the kitchen floor because sitting down in a chair felt like too much of a risk. This was Tuesday. This was also Monday. And the Monday before that.
Her cardiologist had run an EKG. Normal. An echocardiogram. Normal. A Holter monitor captured the rate spikes, but the cardiologist said the heart itself was structurally fine and that the episodes were likely anxiety. Her neurologist mentioned dysautonomia and referred her back to cardiology. Cardiology referred her back to neurology. After nine months, she had 11 different specialists and no treatment plan.
This is not an unusual story. For patients with conditions that affect the autonomic nervous system, the journey to diagnosis is often measured in years, not months. The patients are not imagining their symptoms. The symptoms simply do not fit neatly into the specialty-based structure of conventional medicine.
Understanding the Triad
Three conditions appear together with enough regularity that providers who specialize in this area treat them as a triad: Mast Cell Activation Syndrome (MCAS), Postural Orthostatic Tachycardia Syndrome (POTS), and Ehlers-Danlos Syndrome (EDS).
They are not the same condition. But they share overlapping mechanisms and frequently co-occur, and treating one without understanding the others leads to partial results at best.
MCAS involves mast cells, which are immune cells distributed throughout body tissue. Their normal function is to release inflammatory chemicals, histamine and others, in response to genuine threats. In MCAS, the trigger threshold for these releases becomes extremely low. Almost any stimulus, food, fragrance, temperature change, emotional stress, physical movement, can trigger a release. The result is wide-ranging systemic reactions that seem disconnected: flushing, hives, gastrointestinal distress, swelling, throat tightening, heart palpitations, and anaphylaxis in severe cases.
POTS is a form of dysautonomia, meaning it involves dysfunction in the autonomic nervous system, the part of the nervous system that regulates all the functions the body does automatically: heart rate, blood pressure, breathing, digestion, temperature regulation. In POTS specifically, the regulation of heart rate upon standing breaks down. A normal heart rate increase when moving from lying to standing is around 10-20 beats per minute. In POTS, the increase is 30 beats per minute or more, sustained, producing symptoms ranging from lightheadedness and palpitations to near-syncope and full fainting.
EDS involves the connective tissue. Connective tissue is the structural material found in joints, skin, blood vessel walls, and organs throughout the body. In EDS, that tissue is more elastic than it should be. Joints become hypermobile, stretching beyond normal range. Skin becomes fragile. Blood vessels lose some of their rigidity, which contributes directly to POTS: when veins are too elastic, blood pools in the lower body upon standing rather than returning efficiently to the heart and brain.
The connection between all three goes deeper than structural overlap. Inflammation, particularly the mast-cell-driven inflammation of MCAS, directly worsens joint laxity in EDS. Reducing MCAS-driven inflammation can literally tighten hypermobile joints because inflammation was a component of the instability. This also means that treating MCAS first often improves POTS symptoms, because some of the hemodynamic dysregulation is inflammation-driven.
Who Gets This and Why
There is a consistent pattern in who develops these conditions. They appear far more commonly in women than in men. They frequently emerge or dramatically worsen at hormonal transition points: at puberty, during or after pregnancy, and at perimenopause.
This pattern is not coincidental. The autonomic nervous system is significantly regulated by sex hormones. Estrogen affects mast cell activity. Progesterone affects connective tissue tone and autonomic regulation. When hormonal levels shift, the stability of these systems shifts with them. In people who have a genetic predisposition to any of these conditions, hormonal transitions can push a compensated system into a decompensated one.
This also explains why symptoms often appear “out of nowhere” at age 40 or 42 in women who had been healthy for their entire adult lives. Nothing went wrong suddenly. Something that was always present but compensated crossed a threshold when the hormonal environment changed.
Recognizing this pattern changes the clinical approach. These patients need hormonal evaluation alongside autonomic evaluation, not separate from it. Treating POTS without assessing whether perimenopause is destabilizing the hormonal foundation is treating part of the problem.
What Medical Trauma Looks Like
The patient with MCAS, POTS, or EDS has typically seen many physicians by the time they find someone who understands what is happening. The number 50 is not hyperbole in this space. Patients who have seen more than 50 providers across their diagnostic journey are known quantities in clinics that specialize in these conditions.
The experience of being told that a real, measurable, debilitating symptom is psychological leaves a mark. Patients begin to distrust their own experience. They minimize symptoms when describing them because they have learned that full disclosure leads to dismissal. They become hypervigilant in medical settings, which activates the mast cells further, making their reactions worse in clinical environments, which confirms to the provider that the patient is “anxious.”
Patients who went into anaphylaxis when changing body position too quickly have been told by emergency department physicians that what they experienced was a panic attack. This is not a failure of empathy. It is a failure of clinical education about conditions that medical schools do not teach adequately.
The result is a population of genuinely ill patients who have largely stopped believing that the medical system will help them. The providers who do specialize in this space describe nearly universal medical trauma in their patient population.
What Effective Treatment Looks Like
Treatment for this triad is not one intervention. It is a sequenced approach that addresses multiple systems simultaneously.
For MCAS, the priority is reducing mast cell load. This involves identifying and eliminating triggers where possible, using medications or supplements that stabilize mast cells before they degranulate, and using antihistamines targeting both H1 and H2 receptors. The trigger identification is highly individual. For some patients, specific foods are the primary trigger. For others, it is fragrance, heat, or physical exertion. Systematic elimination and reintroduction identifies the pattern.
Tirzepatide, a second-generation GLP-1 receptor agonist primarily known for its use in diabetes and weight management, has shown direct mast-cell-targeting properties that are relevant to MCAS. This is a newer area of investigation, and the mechanism continues to be studied, but providers working with MCAS patients have noted clinically meaningful improvements in some patients using this medication.
For POTS, interventions target the blood pooling and heart rate dysregulation directly. Increased fluid and sodium intake is often the first step, expanding blood volume so that standing produces less of a hemodynamic drop. Compression garments, particularly compression stockings and abdominal binders, reduce lower-extremity pooling. IV saline infusions can stabilize severely symptomatic patients who cannot maintain adequate volume through oral intake. Medications targeting heart rate or blood pressure are added depending on the specific subtype of POTS present.
For EDS, there is no medication that repairs connective tissue. Physical therapy focused on stabilizing muscles around hypermobile joints is the primary intervention. Understanding which activities and positions worsen symptoms allows patients to make informed choices about movement. And addressing the MCAS-driven inflammation that worsens joint instability often produces noticeable improvements in joint function.
The Hormonal Layer
Hormonal evaluation is essential and frequently omitted. Sex hormone levels, thyroid function, and adrenal cortisol patterns should all be assessed in patients with this triad, particularly women in the perimenopause age range.
Hormonal optimization does not replace the other interventions, but it provides the systemic stability that makes those interventions more effective. A patient whose autonomic nervous system is being destabilized by dramatic hormonal fluctuations will not achieve the same results from POTS protocols as a patient whose hormonal foundation is supported.
These conditions are manageable. Not easily, and not quickly, but with the right clinical approach and realistic expectations, patients do significantly improve. The challenge has never been the absence of effective treatment. It has been getting to the right provider before years of symptoms and 50 specialists have eroded the patient’s willingness to keep trying.
About the Author: This article was written by the clinical education team at Med Matrix, a functional medicine clinic in South Portland, Maine. Med Matrix serves over 3,000 patients with a provider team that specializes in root-cause testing, hormone optimization, and personalized treatment plans.